- Report
- April 2023
- 260 Pages
Global
From €3481EUR$3,600USD£2,948GBP
- Report
- March 2019
- 746 Pages
Global
€21275EUR$22,000USD£18,018GBP
- Report
- January 2019
- 58 Pages
Global
From €9671EUR$10,000USD£8,190GBP
- Report
- January 2019
- 29 Pages
Global
From €9671EUR$10,000USD£8,190GBP
- Report
- January 2019
- 40 Pages
Global
From €9671EUR$10,000USD£8,190GBP
- Report
- January 2019
- 18 Pages
Global
From €9671EUR$10,000USD£8,190GBP
- Drug Pipelines
- January 2019
- 510 Pages
Global
From €21275EUR$22,000USD£18,018GBP
- Report
- April 2018
- 196 Pages
Global
From €21275EUR$22,000USD£18,018GBP
- Report
- July 2020
- 1740 Pages
Global
From €4642EUR$4,800USD£3,931GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €484EUR$500USD£409GBP
- Report
- January 2019
- 35 Pages
Global
From €967EUR$1,000USD£819GBP
Treanda is a chemotherapy drug used to treat certain types of leukemia, including chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL). It is a type of alkylating agent, which works by interfering with the growth of cancer cells. Treanda is administered intravenously and is usually given in combination with other drugs. It is also used to treat certain types of lymphoma and multiple myeloma.
Treanda is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2014. It is marketed by Teva Pharmaceuticals and is available in both generic and branded forms. Other companies that produce Treanda include Mylan, Sun Pharmaceuticals, and Dr. Reddy's Laboratories. Show Less Read more
